Abstracts tagged "epigenetics and interleukins (IL)"

Abstract Number: 923 • 2016 ACR/ARHP Annual Meeting
Retinoic Acid Inhibits Expression of Interleukin 9 By Altering Enhancer Architecture
Daniella Schwartz¹, Francoise Meylan², Hong-Wei Sun³, Han-Yu Shih⁴, Kan Jiang⁴, Franziska Petermann⁴, Richard M. Siegel⁵, Arian Laurence⁶ and John J O'Shea⁷, ¹NIAMS - Rheumatology, National Institutes of Health, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴NIAMS, Rheumatology, National Institutes of Health, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁶University of Oxford, Oxford, United Kingdom, ⁷NIAMS NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD
Background/Purpose: Vitamin A and its major metabolite, retinoic acid (ATRA), modulate T cell function and fitness to shape immune responses. Vitamin A deficiency causes increased…
Abstract Number: 341 • 2012 ACR/ARHP Annual Meeting
Oral Administration of a Novel Small Molecule BET Bromodomain Inhibitor, RVX-297, Reduces Disease Severity in a Rat Collagen-Induced Arthritis Model
R. Jahagirdar¹, S. Attwell¹, E.M. Gesner¹, K.G. McLure¹, H.C. Hansen¹, J. Chen², J. Wu¹, K. Norek¹, N. Shenoy², G.S. Wagner¹ and P. R. Young¹, ¹Resverlogix Corporation, Calgary, AB, Canada, ²Aravasc Inc., Sunnyvale, CA
Background/Purpose: BET (Bromodomain and Extra-Terminal) proteins have recently emerged as a key epigenetic regulator of genes at the transcriptional level and inhibition of their binding…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].